This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Stockwatch Business Reporter

The TSX Venture Exchange fell 4.01 points to 747.11 Wednesday. Since the start of September, the TSX-V has closed up just nine out of 46 trading days, and has declined a total of 277.04 points, or 27 per cent. Despite the decaying exchange, there remain high-profile shell packagers with capital pool shells on the TSX-V who are continuing to do business as usual. Today, for example, a prolific shell-maker from Toronto, Ron Schmeichel, reported that he has already found a qualifying transaction for his Mira IV Acquisition Corp. (MRY), which listed six weeks ago. It plans to acquire Profound Medical Inc., a Toronto medical device company that last year started a phase 1 clinical trial on a "minimally invasive" tool that, delivered through a trans-urethral approach -- be thankful you are unconscious -- uses ultrasound to treat localized prostate cancer. The company's device targets prostate tissue without exposing healthy tissue outside the prostate to harm. Profound Medical recently started a safety and feasibility trial with 30 patients.

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS